On Wednesday, Electromed, Inc. (NYSEMKT:ELMD)’s shares declined -7.17% to $2.20.
Electromed, Inc. (ELMD) proclaimed financial results for the three- and nine-month periods ended March 31, 2015. Net revenues for the third quarter of fiscal 2015 rose about 15% to $4.56 million, contrast to $3.96 million in the same quarter of fiscal 2014. The Company stated net income of $37,000, or $0.00 cents per basic and diluted share, for the third quarter of fiscal 2015, contrast to a net loss of $1,004,000, or ($0.12) per basic and diluted share, for the same period of fiscal 2014.
Growth in total net revenues was attributable to strong results in the home care market where revenue raised by about 18.5%, or $0.6 million, contrast to the same period of fiscal 2014. Home care sales raised due to a greater number of approvals from third party payers, such as insurance companies, Medicare and Medicaid, for the Company’s SmartVest™ products. International sales reduced by 44%, or $128,000, due primarily to the timing of orders placed by international distributors in the first quarter of fiscal 2015. Institutional and government sales raised 30%, or $131,000, contrast to the third quarter of fiscal 2014 as a result of the continued focused efforts of our sales force.
Electromed, Inc. designs, develops, manufactures, markets, and sells airway clearance products in the United States and internationally. It offers SmartVest airway clearance system and related products, which generate high frequency chest wall oscillation that facilitates airway clearance by loosening and mobilizing respiratory secretions in patients’ lungs.
Alexza Pharmaceuticals, Inc. (NASDAQ:ALXA)’s shares dropped -7.26% to $1.15.
Alexza Pharmaceuticals, Inc. (ALXA) stated financial results for the quarter ended March 31, 2015. The net loss and the loss from operations for the first quarter were $0.4 million and $13.0 million, respectively, contrast to $10.7 million and $8.8 million during the same quarter in 2014, respectively. At March 31, 2015, Alexza had merged cash, cash equivalents, marketable securities, and restricted cash of $23.9 million.
During 2013 and 2014, Alexza accomplished production of ADASUVE for commercial launch and initial stocking, which did not utilize Alexza’s full manufacturing capacity. In partnershipwith Teva and Ferrer, Alexza conducted an analysis to evaluate need for the product and cost-effective strategies for ADASUVE commercial production. The analysis comprised of supply chain requirements, production volume and timelines, commercial batch sizes and possible scenarios to make global production more efficient and cost-effective. Earlier this year, Teva and Ferrer offered longer-term ADASUVE orders, allowing Alexza to manufacture ADASUVE in a compriseent manner to take advantage of the efficiencies of continued batch production.
Alexza Pharmaceuticals, Inc., a pharmaceutical company, focuses on the research, development, and commercialization of proprietary products for the acute treatment of central nervous system conditions worldwide.
At the end of Wednesday’s trade, Ceres Inc (NASDAQ:CERE)‘s shares dipped -6.95% to $2.41.
Ceres Inc (CERE) declared that the company has licensed its Persephone bioinformatics software to global seed potato developer, HZPC Holland BV. The software license agreement provides a non-exclusive license to HZPC in addition to professional support services.
HZPC is the most recent multi-national life sciences company to adopt Persephone as its primary genome browser. Originally developed for in-house use by Ceres, the Persephone software allows researchers to store, access and explore DNA databases in much the same way online mapping programs allow users to explore geographic regions and locations. Recently, hundreds of life scientists around the globe are using Persephone.
Ceres, Inc., an agricultural biotechnology company, develops and sells energy crops to produce renewable bioenergy feedstocks in North America. The company’s energy crops comprise sweet sorghum; high biomass sorghum for the generation of renewable electric power and the creation of cellulosic biofuels; switchgrass, a perennial grass; miscanthus, a tall perennial grass for use as an energy crop. Ceres, Inc. markets its seed products under the Blade brand.
RigNet Inc (NASDAQ:RNET), ended its Wednesday’s trading session with -6.90% loss, and closed at $35.15.
RigNet Inc (RNET) stated quarterly results for the quarter ended March 31, 2015.
Quarterly revenue was $77.7 million representing an enhance of $2.6 million, or 3.5%, as contrast to the same quarter last year. The enhance was primarily due to raised revenue-per-site and raised offshore drilling sites served in addition to an additional month of revenue from the Inmarsat Enterprise Energy business unit acquisition, though it was partially offset by reduced Telecommunications Systems Integration (TSI) revenue.
Quarterly Adjusted EBITDA was $17.1 million, or 22.0% of revenue, representing an enhance of $0.9 million, or 5.6%, over the same quarter last year. The enhance primarily resulted from raised revenue from our core offshore rig services, an additional month of revenue from the Inmarsat Enterprise Energy business unit acquisition, cost containment from our resource reallocation plan declared in February and a separate cost savings initiative.
RigNet, Inc. provides digital technology solutions to the oil and gas industry. The company operates through three segments: Eastern Hemisphere, Western Hemisphere, and Telecoms Systems Integration. It offers remote communications services through a controlled and managed Internet protocol/multiprotocol label switching (IP/MPLS) global network, enabling drilling contractors, oil companies, and oilfield service companies to communicate.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.